Clinical significance of nuclear factor |
Shin, Ho Cheol
(Department of Hematology and Oncology, Kyungpook National University Hospital)
Seo, Jongwon (Department of Hematology and Oncology, Kyungpook National University Hospital) Kang, Byung Woog (Department of Hematology and Oncology, Kyungpook National University Hospital) Moon, Joon Ho (Department of Hematology and Oncology, Kyungpook National University Hospital) Chae, Yee Soo (Department of Hematology and Oncology, Kyungpook National University Hospital) Lee, Soo Jung (Department of Hematology and Oncology, Kyungpook National University Hospital) Lee, Yoo Jin (Department of Hematology and Oncology, Kyungpook National University Hospital) Han, Seoae (Department of Hematology and Oncology, Kyungpook National University Hospital) Seo, Sang Kyung (Department of Hematology and Oncology, Kyungpook National University Hospital) Kim, Jong Gwang (Department of Hematology and Oncology, Kyungpook National University Hospital) Sohn, Sang Kyun (Department of Hematology and Oncology, Kyungpook National University Hospital) Park, Tae-In (Department of Pathology, Kyungpook National University Hospital) |
1 | Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. DOI ScienceOn |
2 | Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282. DOI ScienceOn |
3 | Scupoli MT, Donadelli M, Cioffi F, et al. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica 2008;93:524-532. DOI ScienceOn |
4 | The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994. DOI ScienceOn |
5 | Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368-376. DOI ScienceOn |
6 | Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. DOI ScienceOn |
7 | Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1803-1811. DOI ScienceOn |
8 | Espinosa I, Briones J, Bordes R, et al. Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology 2008;53:441-449. DOI ScienceOn |
9 | Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861-1874. DOI |
10 | Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-721. DOI ScienceOn |
11 | Saito B, Shiozawa E, Usui T, et al. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma. Leukemia 2007;21:2563-2566. DOI ScienceOn |
12 | Ahn JY, Seo K, Weinberg OK, Arber DA. The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol 2013;21:79-84. |
13 | Yao X, Zhou L, Han S, Chen Y. High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J Int Med Res 2011;39:1253-1264. DOI |
14 | Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005;65:264-276. |
15 | Kwak JY. Treatment of diffuse large B cell lymphoma. Korean J Intern Med 2012;27:369-377. DOI ScienceOn |
16 | Pavan A, Spina M, Canzonieri V, Sansonno S, Toffoli G, De Re V. Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. Leuk Lymphoma 2008;49:2048-2058. DOI ScienceOn |
17 | Johnson PW. New targets for lymphoma treatment. Ann Oncol 2008;19 Suppl 4:iv56-iv59. |
18 | Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700-2707. |
19 | Bavi P, Uddin S, Bu R, et al. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol 2011;224:355-366. DOI ScienceOn |
20 | Calandra G, Bridger G, Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010;341:173-191. |
21 | Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002;62:3106-3112. |
22 | Okera M, Bae K, Bernstein E, et al. Evaluation of nuclear factor kappaB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int 2011;108(2 Pt 2):E51-E58. DOI ScienceOn |
23 | Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-21638. DOI ScienceOn |
24 | Jung SJ, Kim CI, Park CH, et al. Correlation between chemokine receptor CXCR4 expression and prognostic factors in patients with prostate cancer. Korean J Urol 2011;52:607-611. DOI ScienceOn |
25 | Sekiya R, Kajiyama H, Sakai K, et al. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary. Hum Pathol 2012;43:904-910. DOI ScienceOn |
![]() |